BRAIN.Q named "Best New Technology Solution – Therapeutic” in the 2024 MedTech Breakthrough Awards
Awards recognize the ‘BREAK THROUGH’ companies, people, platforms and products in the health, fitness, and medical technology industries today.
[Jerusalem, IL], May 9, 2024 — BrainQ Technologies, a pioneering company at the forefront of brain longevity therapeutics, proudly announces that it has been awarded "Best New Technology Solution – Therapeutic” in the prestigious MedTech Breakthrough Awards 2024.
This recognition underscores our unwavering dedication to pioneering brain longevity therapeutics, particularly in the realm of stroke recovery. Through our innovative solutions, we are committed to empowering patients, enabling them to regain independence and markedly improving their quality of life.
Celebrating the forefront of innovation in health, fitness, and medical technology, the MedTech Breakthrough Awards recognize outstanding achievements across companies, individuals, platforms, and products that define breakthrough advancements in these industries today.
For comprehensive insights and the full roster of awardees, explore the complete list here.
About the Medtech Breakthrough Awards
The MedTech Breakthrough Awards celebrate innovation in healthcare technology, recognizing advancements in telehealth, electronic health records, mHealth, and patient privacy. With a focus on disrupting and innovating the medical technology industry, these awards highlight breakthroughs that are transforming patient care and outcomes.
In a year marked by unprecedented growth and momentum in digital health, the MedTech Breakthrough Awards provide a platform for companies to stand out in the HealthTech crowd. With record-breaking funding and a surge of companies entering the public sphere, these awards recognize excellence and creativity in driving the future of healthcare technology forward.
About BrainQ
BrainQ is a pioneering brain longevity therapeutics company. The company has received an FDA Breakthrough Device Designation for its first product for Stroke disability.
Product Disclaimer: The product information and treatment claims discussed in this article are based on data from clinical studies. These products or treatments may not be approved or available in all regions. Individual treatment outcomes can vary and are not guaranteed. The mention of clinical trial results does not constitute an endorsement or guarantee of efficacy or safety for any individual. Availability and regulatory status are subject to regional differences. The product is currently approved only in the European Economic Area.
Medical Disclaimer: The information provided in this blog post is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. The content relates to devices manufactured by BRAIN.Q and is not a substitute for professional medical advice, consultation, or care from a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or the use of any medical device. Never disregard professional medical advice or delay in seeking it because of something you have read on this blog.
BRAIN.Q makes no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability with respect to the information, products, services, or related graphics contained in this blog post for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will BRAIN.Q be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising out of, or in connection with, the use of this blog post.
